Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 1-Year High - Should You Buy?

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reached a new 52-week high of $36.74 on recent trading, closing at $36.57, with a trading volume of 549,446 shares.
• Several Wall Street analysts have given positive outlooks for Kiniksa Pharmaceuticals, including a raise of the target price by Wells Fargo from $30 to $42, and a strong-buy rating upgrade by Wall Street Zen.
• Insider trading has been notable, with COO Eben Tessari selling over 13,000 shares, indicating potential profit-taking amidst the stock's recent performance.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $36.74 and last traded at $36.57, with a volume of 549446 shares. The stock had previously closed at $35.71.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

The firm's 50 day moving average is $31.13 and its two-hundred day moving average is $26.70. The stock has a market capitalization of $2.71 billion, a PE ratio of 914.48 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 13,389 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $35.66, for a total value of $477,451.74. Following the sale, the chief operating officer directly owned 44,452 shares of the company's stock, valued at approximately $1,585,158.32. This represents a 23.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider John F. Paolini sold 29,325 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total transaction of $954,528.75. Following the completion of the sale, the insider directly owned 57,403 shares in the company, valued at approximately $1,868,467.65. This represents a 33.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 619,649 shares of company stock worth $20,465,432. Corporate insiders own 53.48% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $31,000. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at $33,000. Finally, Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.